![Premium Content](https://dev.pacbiztimes.com/wp-content/themes/e9bqxucyjgdpwjvsw8/images/premium.gif)
Judge: Amgen will not have to put drug prices in TV ads
![](https://dev.pacbiztimes.com/wp-content/uploads/2014/01/amgen-flagWEB-300x224.jpg)
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →![Premium Content](https://dev.pacbiztimes.com/wp-content/themes/e9bqxucyjgdpwjvsw8/images/premium.gif)
Atara to raise $175M in secondary public offering
![](https://dev.pacbiztimes.com/wp-content/uploads/2019/05/10-Atara-A1-300x224.jpg)
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Amgen’s Otezla could be treatment for COVID-19
![](https://dev.pacbiztimes.com/wp-content/uploads/2019/11/34-amgen-workers-web-300x224.gif)
Amgen’s newly acquired Otezla product line could find a role in a suite of new therapies designed to treat COVID-19 patients. News of the potential for the rheumatoid arthritis product came as the Thousand Oaks-based biotech reported that earnings and revenue shot up in the first quarter. The company’s outlook stayed flat as it shifts Read More →
Read More →![Premium Content](https://dev.pacbiztimes.com/wp-content/themes/e9bqxucyjgdpwjvsw8/images/premium.gif)
MannKind beats earnings estimates
![](https://dev.pacbiztimes.com/wp-content/uploads/2017/06/15-mannkind-web-300x224.jpg)
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →![Premium Content](https://dev.pacbiztimes.com/wp-content/themes/e9bqxucyjgdpwjvsw8/images/premium.gif)
Amgen’s first quarter earnings beat analyst estimates
![](https://dev.pacbiztimes.com/wp-content/uploads/2019/08/23-amgen-web-300x224.gif)
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →